Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-Current Assets (2023 - 2025)

Monte Rosa Therapeutics' Non-Current Assets history spans 3 years, with the latest figure at $55.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 9.49% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $234.5 million, down 9.48%, while the annual FY2025 figure was $55.5 million, 9.49% down from the prior year.
  • Non-Current Assets reached $55.5 million in Q4 2025 per GLUE's latest filing, down from $58.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $70.5 million in Q2 2023 to a low of $55.5 million in Q4 2025.
  • Average Non-Current Assets over 3 years is $64.1 million, with a median of $65.0 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: dropped 1.11% in 2024, then decreased 10.03% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $67.5 million in 2023, then decreased by 9.25% to $61.3 million in 2024, then decreased by 9.49% to $55.5 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Non-Current Assets are $55.5 million (Q4 2025), $58.0 million (Q3 2025), and $60.1 million (Q2 2025).